Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA’s approval of REDEMPLO (plozasiran) on November 18, 2025—marking the company’s first FDA-approved medicine and the first-ever FDA-approved siRNA therapeutic for familial chylomicronemia syndrome (FCS) treatment. This historic approval represents not only a pivotal achievement for Arrowhead but also a breakthrough for the estimated 6,500 Americans living with this severe and rare genetic metabolic disorder.
Familial chylomicronemia syndrome is a devastating, rare disease characterized by triglyceride levels that reach 10 to 100 times higher than normal, typically exceeding 880 mg/dL. Acc...
